GLP-1 receptor agonists × glycemic control

Observational studyCardiovascular diabetology2020

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.

David Thein et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2020

Range includes no effect

No clear effect on glycemic control

+11%−11% to +39%

Bigger than 1 in 10 for glycemic control

As reported

HR 1.11, 95% CI 0.89–1.39

One number in the abstract

the abstract, start to end

for HF-hazard ratios (HR) were 1.11 (95% CI 0.89-1.39) for GLP-1

← favours treatmentfavours comparator →
could be chance
Glycemic control
HR 1.110.89–1.39
GLP-1 receptor agonistsSulfonylureas & glinidesInsulinGlycemic control
1 / 3

20 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 32631337